43 unknown. 43 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 43 | Unknown 43 |
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis 25(OH)D3, vitamin D3 - Multiple Sclerosis, Relapsing-Remitting, Adult ALL | Phase 4 | Unknown | Tehran University of Medical Sciences | 54 | 2022-07-01 | 2022-04-22 |
| Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD Bortezomib - Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity | Phase 4 | Unknown | Hospital General de Mexico | 56 | 2021-12-12 | 2022-01-18 |
| A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase | Phase 4 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 200 | 2021-11-23 | 2022-04-29 |
| Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia Simvastatin - Strains, Acute Lymphoblastic Leukemia | Phase 4 | Unknown | Hospital General de Mexico | 108 | 2021-11-19 | 2022-01-04 |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 200 | 2021-01-01 | 2022-03-16 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Ikervis for DED Due to GVHD Post Allo-HSCT Cyclosporine Ophthalmic - Leukemia (Both ALL and AML), MDS-EB-1 | Phase 4 | Unknown | Singapore Eye Research Institute | 40 | 2019-11-28 | 2020-11-19 |
| Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy Azacytidine, HAG Regimen, Azacytidine - Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia | Phase 4 | Unknown | Shenzhen Second People's Hospital | 114 | 2019-09-01 | 2022-03-15 |
| A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma CODOX-M/IVAC, Decitabine - T-lymphoblastic Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 40 | 2018-06-01 | 2018-09-14 |
| Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Decitabine, Daunorubicin, Cytarabine, Mitoxantrone, Cytarabine - Acute Myeloid Leukemia | Phase 4 | Unknown | The First Hospital of Jilin University | 180 | 2017-01-01 | 2017-01-20 |
| Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Imatinib, Nilotinib - Chronyc Myeloid Leukemia | Phase 4 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 450 | 2016-11-11 | 2022-01-20 |
| ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Anti-human Thymoglobulin, Placebo - Lymphoblastic Lymphoma | Phase 4 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 130 | 2016-10-01 | 2016-10-25 |
| G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor GM-CSF, G-CSF, GM-CSF and G-CSF - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 4 | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 405 | 2016-09-27 | 2018-10-17 |
| Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd), Cytarabine(Actavis Italy S.p.A), Fludarabine (Bayer) - Leukemia | Phase 4 | Unknown | Chinese PLA General Hospital | 80 | 2016-07-01 | 2016-05-27 |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Dasatinib 50 MG - Chronic Myelogenous Leukemia | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2016-04-01 | 2017-07-13 |
| Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Nilotinib - Leukemia, Chronic Myeloid | Phase 4 | Unknown | Samsung Medical Center | 40 | 2015-04-01 | 2015-03-17 |
| Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Aprepitant - Leukemia, Lymphoma | Phase 4 | Unknown | Sun Yat-sen University | 85 | 2015-04-01 | 2015-01-27 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Imatinib - Chronic Myeloid Leukemia | Phase 4 | Unknown | Cttq | 90 | 2015-02-01 | 2014-12-15 |
| Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy Mercaptopurine - Acute Lymphoblastic Leukemia | Phase 4 | Unknown | Shandong University | 500 | 2015-01-01 | 2019-04-23 |
| Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Interferon-alpha - Acute Myeloid Leukemia | Phase 4 | Unknown | Peking University People's Hospital | 40 | 2013-10-01 | 2016-09-29 |
Showing 20 of 43. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Leukemia, Myeloid, Acute (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Recurrence (4) · Leukemia, Promyelocytic, Acute (3) · Leukemia, Myeloid, Chronic-Phase (2) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Dwarfism (1) · Febrile Neutropenia (1) · Hepatoblastoma (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Hematologic Diseases (43) · Hemic and Lymphatic Diseases (43) · Neoplasms by Histologic Type (43) · Neoplasms (42) · Leukemia, Myeloid (23) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Leukemia, Lymphoid (18) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Disease Attributes (13) · Bone Marrow Diseases (10)
Cytarabine (11) · Idarubicin (8) · Cyclophosphamide (5) · Dexamethasone (4) · Granulocyte Colony-Stimulating Factor (4) · Mercaptopurine (4) · Methotrexate (4) · Vincristine (4) · fludarabine (4) · Daunorubicin (3) · Decitabine (3) · Imatinib Mesylate (3) · Arsenic Trioxide (2) · Busulfan (2) · Dasatinib (2)
Shenzhen Second People's Hospital (3) · Hospital General de Mexico (2) · PETHEMA Foundation (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Sun Yat-sen University (2) · Changhai Hospital (1) · Chinese Academy of Medical Sciences (1) · Chinese PLA General Hospital (1) · Cttq (1) · East Valley Hematology and Oncology Medical Group (1) · German AML Cooperative Group (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Guangdong Provincial People's Hospital (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)
China (16) · Germany (3) · Mexico (3) · Denmark (2) · Italy (2) · Singapore (2) · Spain (2) · India (1) · Malaysia (1) · Netherlands (1) · Russia (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Adolfo Martinez Tovar, PhD (2) · Ajay Vora (1) · Allen Yeoh, MBBS (1) · Changgang Li, M.D. (1) · Christina Peters, Prof. MD PhD (1) · Daihong Liu, Doctor (1) · Dongbo Lai, M.D. (1) · Eva Lengfelder, MD, PhD (1) · Fabrizio Pane (1) · Fang Yongjun, Ph.D (1) · Franco Locatelli, Prof. MD PhD (1) · Gao Fei, Ph.D (1) · Gerhard Ehninger, MD (1) · Giovanni Martinelli, MD (1)
PMID 10231138, PMID 10583235, PMID 11863096, PMID 12627513, PMID 14585365, PMID 16110027, PMID 16197446, PMID 17410187, PMID 18398750, PMID 18626005, PMID 19167677, PMID 19822296, PMID 19951974, PMID 20542125, PMID 20625136, PMID 22318524, PMID 22512017, PMID 22677206, PMID 22871557, PMID 22966847, PMID 23376821, PMID 23383989, PMID 25314773, PMID 25528350, PMID 26230956, PMID 28116786, PMID 29250743, PMID 30044693, PMID 30076280, PMID 30872105, PMID 30957229, PMID 32519032, PMID 33495363, PMID 35154096, PMID 35714315, PMID 36856978, PMID 37276496, PMID 3896457, PMID 7581076
2005 (1)